Tolerability, pharmacokinetics and pharmacodynamics of etamicastat administered as multiple escalating doses in male patients with hypertension

Trial Profile

Tolerability, pharmacokinetics and pharmacodynamics of etamicastat administered as multiple escalating doses in male patients with hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2014

At a glance

  • Drugs Etamicastat (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
  • Sponsors Bial
  • Most Recent Events

    • 12 Jan 2014 New trial record
    • 29 Nov 2013 Results published in Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top